Dr Susan Kohlhaas: key facts
- Kind of voice
- Sector leader
- Role
- Executive Director of Research and Partnerships at Alzheimer's Research UK
- Quoted on
- Dementia
- Tracked press citations
- 6
- Most recently quoted
- 30 Sept 2026
“Dementia is the defining health challenge of our time and meeting it requires ambition and collaboration on a global scale. The Dementia Frontiers Fund represents a bold new approach — bringing together world-leading scientists and partners to pursue the breakthroughs that could transform our understanding and treatment of the diseases that cause dementia.”
What Dr Susan Kohlhaas has said
“Today's disappointing announcement on semaglutide will come as a blow for people affected by Alzheimer's. These trial results are another reminder that Alzheimer's is driven by several different biological processes. No single approach is likely to be enough.”
Executive Director of Research and Partnerships at Alzheimer's Research UK · Dementia · 30 Sept 2026 · Weight loss drug does not slow Alzheimer’s, says drug maker ↗
“These trial results are another reminder that Alzheimer's is driven by several different biological processes. No single approach is likely to be enough.”
Alzheimer's Research UK · Dementia · 30 Sept 2026 · Obesity drug semaglutide fails to slow Alzheimer's ↗
“The lowest dementia risk was seen in people drinking around two to three cups of coffee or one to two cups of tea a day. This level of caffeine intake also linked to slightly better scores on memory and thinking tests, although the differences were small.”
Executive Director of Research at Alzheimer's Research UK · Dementia · 30 Sept 2026 · Could tea or coffee reduce dementia risk? Here’s what you need to know ↗
“This review is attempting to paint an entire class of drugs with the same brush even though we know different anti-amyloid treatments can act in different ways.”
Executive Director of Research and Partnerships at Alzheimer's Research UK · Dementia · 30 Sept 2026 · Leaders in the dementia field react to a report with ‘major limitations’ labelling Alzheimer’s drugs as ineffective ↗
“This study alone isn't enough to tell us whether HRT should be used to reduce dementia risk, but it provides further evidence that the timing of HRT and a woman's hormonal history may matter.”
Executive director of research and partnerships at Alzheimer's Research UK · Dementia · 27 Aug 2026 · Women using HRT at lower risk of dementia, study suggests ↗
Where Dr Susan Kohlhaas has been quoted
- Alzheimer’s Research UK and Gates Ventures launch global fund to tackle the roadblocks in dementia research preventing progressalzheimersresearchuk.org · 30 Sept 2026
- Weight loss drug does not slow Alzheimer’s, says drug makeralzheimersresearchuk.org · 30 Sept 2026
- Obesity drug semaglutide fails to slow Alzheimer'sbbc.com · 30 Sept 2026
- Could tea or coffee reduce dementia risk? Here’s what you need to knowalzheimersresearchuk.org · 30 Sept 2026
- Leaders in the dementia field react to a report with ‘major limitations’ labelling Alzheimer’s drugs as ineffectivealzheimersresearchuk.org · 30 Sept 2026
- Women using HRT at lower risk of dementia, study suggeststheguardian.com · 27 Aug 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.